Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial

Diabetes, Obesity and MetabolismVaduganathan M, Inzucchi SE, Sattar N, et al. | October 12, 2021


In patients with type 2 diabetes and cardiovascular disease, researchers examined how empagliflozin vs placebo influences subsequent insulin initiation or dosing changes.

  • A total of 7,020 patients received empagliflozin 10 mg, 25 mg, or placebo in EMPA-REG OUTCOME.

  • There were 3,633 (52%) participants who were not receiving insulin treatment at baseline; in these patients, empagliflozin led to a reduction in new use of insulin vs placebo by 60%.

  • A total of 3,387 (48%) patients were using insulin at baseline; empagliflozin use in these patients lowered the necessity for a greater than 20% insulin dose increase by 58% and increased the proportion achieving sustained greater than 20% insulin dose reductions without subsequent increases in HbA1c compared with placebo (9.2% vs. 4.9%).

  • Overall, insulin initiation and substantial increases in insulin dose are markedly and durably delayed when empagliflozin is provided, with attainment of sustained reductions in insulin requirements over time.

Read the full article on Diabetes, Obesity and Metabolism